Clinical trial
A Phase II, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in Patients With CD30-positive Cutaneous T-cell Lymphoma (CTCL)
NCT07717580 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in Patients With CD30-positive Cutaneous T-cell Lymphoma (CTCL)
- Lead sponsor
- Peking University First Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- July 31, 2026
- Completion date
- December 30, 2028
- Enrollment
- 46 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cutaneous t-cell lymphoma/mycosis fungoides, primary cutaneous anaplastic large cell lymphoma